INTRODUCTION AND OBJECTIVES: Micro RNAs (miRNA) are short non-coding RNA which are associated with posttranscriptional regulation of gene expression. As clear cell renal cell carcinoma (ccRCC) remains the most common primary renal malignancy and accounts for the majority of more than 14,000 deaths from renal malignancies each year, identification of miRNA signatures may portend prognostic significance could help subset patients with ccRCC eventually leading to therapeutic pathways. miRNAs have demonstrated importance in intratumor communication in ccRCC, however there are no established miRNA biomarkers. In this study, we sought to create a miRNA signature to predict risk overall mortality in patients with ccRCC.
INTRODUCTION AND OBJECTIVES: Micro RNAs (miRNA) are short non-coding RNA which are associated with posttranscriptional regulation of gene expression. As clear cell renal cell carcinoma (ccRCC) remains the most common primary renal malignancy and accounts for the majority of more than 14,000 deaths from renal malignancies each year, identification of miRNA signatures may portend prognostic significance could help subset patients with ccRCC eventually leading to therapeutic pathways. miRNAs have demonstrated importance in intratumor communication in ccRCC, however there are no established miRNA biomarkers. In this study, we sought to create a miRNA signature to predict risk overall mortality in patients with ccRCC.
METHODS: Patient's clinical data and level 3 miRNA expression profiles were obtained from the Cancer Genome Atlas (TCGA) repository. Clinical data was correlated with miRNA expression data. Regression analysis, Kaplan-Meier curves, and Heatmap clustering were performed using R packages ComplexHeatmap, Tidyverse, and Survival. Statistical analysis was performed using R Studio v3.4.4. Significant miRNAs were isolated and a diagnostic high, medium, and low score were created correlating to miRNA expression levels of each patient.
RESULTS: We identified 4 miRNAs (mir-204, mir-181a-1, mir29b-1, let-7d) that significantly affected survival and created a weighted score from these. (Score [ (0.776Âhsa-mir-204 )þ(-0.507Â hsa-mir-181a-1)þ(-0.459Âhsa-mir-29b-1)þ(-0.42Âhas-let-7d)) We were able to subset the cohort using hierarchical clustering into 3 survival categories: low, medium, and high. The low, medium, and high score groups had 278, 84, and 103 subjects respectively. Subjects with a medium and high miRNA score show a decreased significance, p < 0.05 and p < 0.00005 respectively (Figure 1 ). On multivariate analysis, medium and high score along with age, nodal status, metastatic deposit, and T3 or greater lesion were all independently associated with overall survival. CONCLUSIONS: We have created a novel miRNA signature to predict survival in ccRCC. Prospective validation of these markers is ongoing along with further determination of let-7d's role in aggressive tumor development. Papillary Renal Cell Carcinoma (pRCC) is the second most common variant of renal cell carcinoma accounting for approximately 15% of these cases. Currently, there are no widely adopted biomarkers that predict patient outcomes with pRCC. The aim of this study is to create a diagnostic score based on identified miRNA signatures that could be used predict patient survival.
METHODS: Patient's clinical data and level 3 miRNA expression profiles was obtained from the Cancer Genome Atlas (TCGA) repository, an NIH funded open genomic database. Clinical data was correlated with miRNA expression data, and regression analysis Kaplan-Meier curves and Heatmap clustering were performed using R packages ComplexHeatmap and Survival regression. Statistical analysis was also performed using R Studio v3.4.4. Significant miRNAs were isolated and a diagnostic high and low score was created correlating to a miRNA expression levels.
RESULTS: A total of 276 patients were identified who met inclusion criteria and included in this study. Two miRNAs, hsa-mir-335 and has-mir-5010, were identified using regression analysis to be most associated with overall survival. Clustering analysis produced 213 patients with a high score and 63 patients with a low score. Patients with a low score showed a significant decrease in survival(p<0.0001) (Figure 1 ). This was validated in multivariate analysis with known risk factors.
CONCLUSIONS: We have created a novel miRNA signature to predict survival in pRCC using previously unreported miRNA biomarkers. hsa-mir-335 has been identified in gastric cancer as biomarker and is upstream chromosome 7q from MET, a well-known amplified gene in pRCC. hsa-mir-5010 has been used a biomarker in colon cancer but has no validated targets currently. Prospective validation of these markers is ongoing along with further determination of mir-5010 role in disease progression in underway.
Source of Funding: none

MP19-10 PROGNOSTIC SIGNIFICANCE OF C-REACTIVE PROTEIN ON SURVIVAL IN PATIENTS WITH NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA: AN INTERNATIONAL MULTI-RACIAL STUDY
Masahiro Toide*, Kazutaka Saito, Yosuke Yasuda, Kenji Tanabe, Shohei Fukuda, Hiroshi Fukushima, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Tokyo, Japan; Dattataya Patil, Atlanta, GA; Brittney Cotta, Sunil Patel, San Diego, CA; Viraj Master, Atlanta, GA; Ithaar Derweesh, San Diego, CA; Yasuhisa Fujii, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Papillary renal cell carcinoma (papRCC) is the second most common subtype of RCC, nonetheless, prognostic significance of clinical parameters in patients with papRCC is still controversial. C-reactive protein (CRP) is a potential biomarker for clear cell RCC (Saito K, Nat Rev Urol, 2011; Johnson TV, Urology, 2010) , however, associations of CRP and prognosis for papRCC have not been investigated. We evaluated the prognostic impact of CRP for patients with surgically treated nonmetastatic papRCC in the international multi-racial series.
METHODS: We established international multi-racial dataset (Tokyo Medical and Dental University, Japan; University of California San Diego, CA; Emory University, GA) of surgically treated 3799 RCC patients. Of these patients, 400 patients with non-metastatic papRCC were enrolled for analysis. Variables including pathological T stage (pT stage), race, age, sex, type of surgery and CRP were evaluated. The elevation of pretreatment CRP was defined as a level of more than 10 mg/ L. Primary endpoint was recurrence-free survival (RFS), which was estimated using Kaplan-Meier method. Associations of RFS with clinical covariates were investigated by using Cox proportional hazard model. RESULTS: Enrolled 400 patients included 50 Asian, 155 Caucasian, 174 African-American, and 21 other racial patients. The patients for each pT stage (pT1/2/3/4) were 313/46/32/3. The elevations of pretreatment CRP were found in 48 patients (12%). During the follow up period (median 16 months), 30 patients (8%) had recurrences. RFS rates for the entire cohort were 95% at 1 year, 91% at 3 years and 87% at 5 years, respectively. In multivariate analysis, pretreatment CRP was a significant prognostic factor for RFS as well as pT stage. RFS rates were significantly worse in patients with elevated CRP (hazard ratio 2.47, 95% confidence interval 1. 03-5.48; p[0.043) . The 3 year RFS rates of the patients with elevated CRP (76%) was significantly worse than that of patients without elevated CRP (93%)(p [ 0.0012; Figure) .
CONCLUSIONS: CRP is a significant prognostic factor in patients with non-metastatic papRCC in the international multi-racial database. (ESRD) and small renal masses (SRM) suspicious for renal cell carcinoma (RCC) are often urged to undergo radical nephrectomy (RN) prior to kidney transplant. However, is active surveillance (AS) underutilized in this population? We endeavored to compare clinicopathologic characteristics and outcomes of RN for SRM in patients with ESRD before or after transplant.
Source of
METHODS: We performed a retrospective review of patients with ESRD (GFR <15mL/min) who underwent RN for pathologically confirmed RCC between 2000-2018 at a high volume kidney transplant institution. Group 1 consisted of patients who underwent RN after
